Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · June 13, 2024

Tofacitinib for the Treatment of Refractory Celiac Disease Type II

Clinical Gastroenterology and Hepatology


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Gastroenterology and Hepatology
Enduring clinical remission in refractory celiac disease type II with tofacitinib: an open-label clinical study
Clin. Gastroenterol. Hepatol. 2024 May 29;[EPub Ahead of Print], T Dieckman, M Schumann, H Beaumont, HJ Bontkes, F Koning, G Bouma, , V Byrnes, J McCarthy, A Neefjes-Borst, C Loddenkemper, MO Weegh, KEA Lundin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading